ORIC Pharmaceuticals Inc (ORIC)
8.55
-0.25
(-2.84%)
USD |
NASDAQ |
May 24, 16:00
8.53
-0.02
(-0.23%)
After-Hours: 20:00
ORIC Pharmaceuticals Enterprise Value: 259.68M for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 259.68M |
| May 23, 2024 | 276.54M |
| May 22, 2024 | 301.48M |
| May 21, 2024 | 282.61M |
| May 20, 2024 | 295.42M |
| May 17, 2024 | 300.81M |
| May 16, 2024 | 291.37M |
| May 15, 2024 | 310.92M |
| May 14, 2024 | 296.09M |
| May 13, 2024 | 288.00M |
| May 10, 2024 | 289.35M |
| May 09, 2024 | 323.73M |
| May 08, 2024 | 330.48M |
| May 07, 2024 | 331.15M |
| May 06, 2024 | 314.97M |
| May 03, 2024 | 337.89M |
| May 02, 2024 | 325.08M |
| May 01, 2024 | 312.27M |
| April 30, 2024 | 278.56M |
| April 29, 2024 | 238.11M |
| April 26, 2024 | 227.32M |
| April 25, 2024 | 200.35M |
| April 24, 2024 | 227.99M |
| April 23, 2024 | 274.52M |
| April 22, 2024 | 271.14M |
| Date | Value |
|---|---|
| April 19, 2024 | 302.83M |
| April 18, 2024 | 324.41M |
| April 17, 2024 | 341.26M |
| April 16, 2024 | 320.34M |
| April 15, 2024 | 326.41M |
| April 12, 2024 | 343.94M |
| April 11, 2024 | 357.42M |
| April 10, 2024 | 357.42M |
| April 09, 2024 | 402.60M |
| April 08, 2024 | 407.99M |
| April 05, 2024 | 422.82M |
| April 04, 2024 | 437.66M |
| April 03, 2024 | 451.14M |
| April 02, 2024 | 503.73M |
| April 01, 2024 | 554.97M |
| March 28, 2024 | 718.23M |
| March 27, 2024 | 699.03M |
| March 26, 2024 | 698.69M |
| March 25, 2024 | 698.69M |
| March 22, 2024 | 729.01M |
| March 21, 2024 | 774.83M |
| March 20, 2024 | 759.33M |
| March 19, 2024 | 756.63M |
| March 18, 2024 | 780.89M |
| March 15, 2024 | 809.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-128.03M
Minimum
May 09 2022
1.230B
Maximum
Dec 24 2020
325.87M
Average
276.54M
Median
May 23 2024
Enterprise Value Benchmarks
| Geron Corp | 1.704B |
| Verastem Inc | 56.41M |
| Karyopharm Therapeutics Inc | 146.14M |
| Syndax Pharmaceuticals Inc | 1.280B |
| Arvinas Inc | 1.242B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.01M |
| Total Expenses (Quarterly) | 28.99M |
| EPS Diluted (Quarterly) | -0.37 |
| Earnings Yield | -21.17% |